Pharmaceutical composition and methods for producing dopamine agonist activity

Abstract

Methods and compositions using as active ingredients 2-(3H)-indolones whose structures having an aminoalkyl substituent at position 4 and a hydroxy group at position 7 of the indolone nucleus are used to produce selective dopaminergic activity resulting in improved kidney function, relief of the symptoms of congestive heart failure, long lasting anti-hypertensive activity and anti-anginal activity. A species of the active ingredients is 4-di-n-propylaminoethyl-7-hydroxy-2(3H)-indolone or its salts.

What is claimed is: 
     
       1. A pharmaceutical composition having dopamine agonist activity comprising a nontoxic but effective therefor quantity of a compound of the structural formula: ##STR4## in which R is amino, lower alkylamino, di-lower alkyl amino, di-N-allylamino or N-allyl-N-lower alkyl amino and n is an integer of 1-3; or a pharmaceutically acceptable, acid addition salt thereof, combined with a pharmaceutical carrier in dosage unit form. 
     
     
       2. The composition of claim 1 in which the compound is 4-(di-n-propylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof. 
     
     
       3. The composition of claim 1 in which the compound is a 4-(aminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof. 
     
     
       4. The composition of claim 1 in which the compound is 4-(di-allylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof. 
     
     
       5. The composition of claim 2 in which the dopamine agonist activity is manifested in anti-anginal pectoris activity. 
     
     
       6. The composition of claim 3 in which the dopamine agonist activity is manifested by beneficial treatment of congestive heart failure. 
     
     
       7. The method of producing dopamine agonist activity in a subject in need thereof comprising administering orally or parenterally an effective therefor, nontoxic quantity of a compound of the structural formula: ##STR5## in which R is amino, lower alkylamino, di-lower alkylamino, di-N-allylamino or N-allyl-N-lower alkyl amino and n is an integer of 1-3; or a pharmaceutically acceptable, acid addition salt thereof, combined with a pharmaceutical carrier in dosage unit form. 
     
     
       8. The method of claim 7 in which the compound is 4-(di-n-propylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof. 
     
     
       9. The method of claim 7 in which the compound is a 4-(aminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof. 
     
     
       10. The method of claim 7 in which the compound is 4-(di-allylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof.